Rozlytrek vs. Vitrakvi

Are Vitrakvi and Rozlytrek the Same Thing?

Rozlytrek (entrectinib) and Vitrakvi (larotrectinib) are kinase inhibitors used to treat adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.

Rozlytrek is also used to treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.

Side effects of Rozlytrek and Vitrakvi that are similar include fatigue, constipation, dizziness, diarrhea, nausea, shortness of breath, muscle pain, weight gain, cough, vomiting, fever, and joint pain.

Side effects of Rozlytrek that are different from Vitrakvi include changes in taste, fluid retention (edema), impaired sense of touch, cognitive impairment, and vision disorders (blurred vision, light sensitivity, double vision, visual impairment, flashes of light, cataracts, and floaters).

Side effects of Vitrakvi that are different from Rozlytrek include anemia, increased AST, increased ALT, swelling of extremities, abdominal pain, headache, stuffy nose, muscle weakness, back pain, pain in extremities, loss of appetite, and high blood pressure (hypertension).

Both Rozlytrek and Vitrakvi may interact with grapefruit and grapefruit products and strong or moderate CYP3A inhibitors or inducers.

Rozlytrek may also interact with medications that prolong the QT/QTc interval.

What Are Possible Side Effects of Rozlytrek?

Common side effects of Rozlytrek include:

  • fatigue,
  • constipation,
  • changes in taste,
  • fluid retention/swelling (edema),
  • dizziness,
  • diarrhea,
  • nausea,
  • impaired sense of touch,
  • shortness of breath,
  • muscle pain,
  • cognitive impairment,
  • weight gain,
  • cough,
  • vomiting,
  • fever,
  • joint pain, and
  • vision disorders
    • blurred vision,
    • light sensitivity,
    • double vision,
    • visual impairment,
    • flashes of light,
    • cataracts, and
    • floaters

What Are Possible Side Effects of Vitrakvi?

Side effects of Vitrakvi nclude<:/p>

  • fatigue,
  • nausea,
  • dizziness,
  • vomiting,
  • anemia,
  • increased AST,
  • cough,
  • increased ALT,
  • constipation,
  • diarrhea,
  • fever,
  • swelling of extremities,
  • abdominal pain,
  • headache,
  • shortness of breath,
  • stuffy nose,
  • weight gain,
  • joint pain,
  • muscle pain,
  • muscle weakness,
  • back pain,
  • pain in extremities,
  • loss of appetite, and
  • high blood pressure (hypertension)

What Is Rozlytrek?

Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive; and adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.

What Is Vitrakvi?

Vitrakvi (larotrectinib) is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

SLIDESHOW

Lung Cancer: Early Signs, Symptoms, Stages See Slideshow

What Drugs Interact With Rozlytrek?

Rozlytrek may interact with grapefruit and grapefruit products, strong or moderate CYP3A inhibitors or inducers, and medications that prolong the QT/QTc interval. Tell your doctor all medications and supplements you use. Rozlytrek is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Rozlytrek and for 5 weeks following the final dose. Males with female partners of reproductive potential are advised to use effective contraception during treatment with Rozlytrek and for 3 months after the final dose. It is unknown if Rozlytrek passes into breast milk. Because of the potential adverse reactions in breastfed children, breastfeeding is not recommended during treatment with Rozlytrek and for 7 days after the final dose.

What Drugs Interact With Vitrakvi?

Vitrakvi may interact with strong CYP3A4 inhibitors including grapefruit or grapefruit juice, strong CYP3A4 inducers including St. John's wort, and sensitive CYP3A4 substrates. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Vitrakvi; it may harm a fetus. Breastfeeding is not recommended while using Vitrakvi and for 1 week after the final dose.

How Should Rozlytrek Be Taken?

The recommended dosage of Rozlytrek for ROS1-Positive non-small cell lung cancer is 600 mg orally once daily. The recommended adult dosage of Rozlytrek for NTRK gene fusion-positive solid tumors is 600 mg orally once daily. The recommended dosage of Rozlytrek is based on body surface area.

How Should Vitrakvi Be Taken?

The recommended dosage of Vitrakvi in adult and pediatric patients with a body surface area of at least 1.0 meter-squared is 100 mg orally twice daily. The recommended dosage of Vitrakvi in in pediatric patients with body surface area of less than 1.0 meter-squared is 100 mg/m2 orally twice daily.

QUESTION

Lung cancer is a disease in which lung cells grow abnormally in an uncontrolled way. See Answer
Disclaimer

All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).

Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.

Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.

The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.

As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.

Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.

If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.

You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.

References


Genentech USA, Inc. Rozlytrek Product Information.

https://www.rozlytrek.com

Bayer. Vitrakvi Product Information.

https://www.hcp.vitrakvi-us.com

Health Solutions From Our Sponsors